$6.85 0.04 (+0.59%)
11/24/2009 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Member Avatar apiperisdown (77.56) Submitted: 11/5/2008 6:37:58 PM : Outperform Start Price: $3.38 EXEL Score: +82.15

Insider buying indicates that they are not that bummed that GSK passed. CEO put a million dollar bet on his company right before Halloween. Trick? or Treat? I'm gonna take a shot and say treat. Giddy up.

Report this Post 0 Comments

Featured Broker Partners